Johnson & Johnson reported solid Q3 sales growth and slightly raised their EPS guidance, signaling management's confidence in the business despite ongoing challenges like OTC product recalls and higher expenses. Strong performance of new pharmaceutical products and strategic investments in innovation suggest positive momentum. The favorable guidance and focus on growth initiatives are likely to have a positive impact on the stock in the short term.

[1]